NorthStar and YAP Therapeutics Partner to Develop Radiopharmaceutical Products

• NorthStar Medical Radioisotopes and YAP Therapeutics have partnered to develop and produce radiopharmaceuticals for cancer and chronic diseases.

• NorthStar will supply actinium-225 (Ac-225) and provide CDMO services to support YAP’s biologic treatments.

NorthStar Medical Radioisotopes and YAP Therapeutics, Inc. have entered a collaboration to develop advanced radiopharmaceuticals targeting cancer and other chronic conditions. The partnership leverages NorthStar’s expertise in medical radioisotope production and YAP’s biologic and regenerative medicine platforms.

Under this agreement, NorthStar will supply non-carrier added actinium-225 (n.c.a. Ac-225), a critical radioisotope for targeted therapies. Additionally, NorthStar will provide radiopharmaceutical CDMO services, including preparing clinical trial-ready doses of YAP Therapeutics’ investigational medicines. Upon regulatory approval, NorthStar may also supply radionuclides for commercial use.

“NorthStar leads in medical radioisotope development and production. This agreement furthers our goal to deliver radiopharmaceuticals to patients,” said Frank Scholz, President and CEO of NorthStar. “We are excited to partner with YAP Therapeutics, merging our technology with their biologics to target specific therapies.”

Olav Bergheim, Founder and Chairman of YAP Therapeutics, highlighted the potential of the collaboration: “We are thrilled about partnering with NorthStar to improve cancer treatment. Their radiopharmaceutical expertise complements our biologics development.”